Core Scientific, Inc./tx
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 09/30/24 | FY 06/30/24 | FY 12/31/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $319.0M | $510.7M | — | — | $502.4M |
| Selling, general & administrative | $159.2M | $113.7M | — | — | $108.1M |
| Research and development | — | $11.8M | — | — | $7.2M |
| Operating income | -$245.6M | -$142.1M | — | — | $9.0M |
| Pretax income | -$288.0M | -$1.4B | — | — | -$245.8M |
| Income tax expense | $583,000 | $859,000 | — | — | $683,000 |
| Net income | -$288.6M | -$1.4B | — | — | -$246.5M |
| Balance Sheet | |||||
| Cash and equivalents | $311.4M | $836.2M | — | — | $50.4M |
| Current assets | $895.5M | $904.0M | — | — | $97.0M |
| Total assets | $2.3B | $1.5B | $824.6M | $664.2M | $712.2M |
| Current liabilities | $781.4M | $134.6M | — | — | $488.4M |
| Total liabilities | $3.3B | $2.4B | — | — | $1.3B |
| Stockholders' equity | -$962.7M | -$943.0M | -$826.7M | -$1.2B | -$596.9M |
| Cash Flow Statement | |||||
| Cash from operations | $278.2M | $42.9M | — | — | $65.1M |
| Depreciation and amortization | $68.9M | $113.2M | — | — | $96.0M |
| Stock-based compensation | $98.2M | $51.9M | — | — | $58.9M |
| Capital expenditure | $729.0M | $95.0M | — | — | $16.2M |
| Free cash flow | -$450.8M | -$52.1M | — | — | $49.0M |
| Share repurchases | — | $0 | — | — | $0 |
| Impairments | $11.4M | $122.9M | — | — | $0 |
Shares outstanding 317.9M · Free float 56.0%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.